Presentations to illustrate wide applicability of JuvImmune and JuvaVax
PLEASANTON, Calif., Sept. 26 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today six scientific presentations at the upcoming IDSA meeting on October 6, 2007. The data will cover the consistency in multiple species of JuvImmune immunostimulant and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.
"We are pleased that the company and its collaborators are presenting a number of high quality papers at the IDSA meeting in San Diego," said Martin D. Cleary, Co-founder, Chairman and CEO of Juvaris. "We believe these presentations demonstrate the wide applicability of the Juvaris JuvImmune and JuvaVax vaccine platforms for prophylaxis and treatment of infectious disease."
Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.
When combined with disease-specific antigens, the technology creates
JuvaVax vaccines capable of activating substantial antibody- and
cell-mediated immune responses, particularly induction of cytotoxic T
lymphocytes (CTL). Immunological responses elicited by the lipid-DNA
complexes have been successfully demonstrated in both prophylactic and
therapeutic settings in a variety of mammals including rodents, rabbits,
cats, dogs and non-human primates. This platform provides the opportunity
to develop many disease-specific immunotherapy products, for which
|SOURCE Juvaris BioTherapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved